

1 Heterogeneity in statin responses explained by variation in the human gut microbiome

2 **Authors:** Tomasz Wilmanski¹, Sergey A. Kornilov¹, Christian Diener¹, Mathew Conomos²,
3 Jennifer C. Lovejoy¹, Paola Sebastiani³, Eric S. Orwoll⁴, Leroy Hood¹, Nathan D. Price⁵, Noa
4 Rappaport^{1,*}, Andrew T. Magis^{1,*}, Sean M. Gibbons^{1,6,7,*}

5 **Affiliations:**

6 ¹ Institute for Systems Biology, Seattle, WA, USA

7 ² University of Washington, Genetic Analysis Center, Seattle, WA, USA

8 ³ Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA,
9 USA

10 ⁴ Oregon Health Sciences University, Portland, OR, USA

11 ⁵ Onegevity (a division of Thorne HealthTech), New York, NY, USA

12 ⁶ University of Washington, Department of Bioengineering, Seattle, WA, USA

13 ⁷ University of Washington, eScience Institute, Seattle, WA, USA

14 * Corresponding authors: noa.rappaport@isbscience.org, amagis@isbscience.org,
15 sgibbons@isbscience.org

16 **Abstract:** Statins remain one of the most prescribed medications worldwide. While effective in
17 decreasing atherosclerotic cardiovascular disease risk, statin use is associated with several side
18 effects for a subset of patients, including disrupted metabolic control and increased risk of type
19 II diabetes. We investigated the potential role of the gut microbiome in modifying patient
20 response to statin therapy. In a cohort of >1840 individuals, we find that the hydrolyzed
21 substrate for 3-hydroxy-3-methylglutarate-CoA (HMG-CoA) reductase, HMG, may serve as a
22 reliable marker for statin on-target effects. Through exploring gut microbiome associations
23 between blood-derived measures of statin effectiveness and metabolic health parameters
24 among statin users and non-users, we find that heterogeneity in statin response is associated
25 with variation in the gut microbiome. A *Bacteroides* rich, α -diversity depleted, microbiome
26 composition corresponds to the strongest statin on-target response, but also greatest disruption
27 to glucose homeostasis, indicating lower treatment doses and/or complementary therapies may
28 be beneficial in those individuals. Our findings suggest a potential path towards personalizing
29 statin treatment through gut microbiome monitoring.

30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51

52 **Introduction:**

53 Between 25% - 30% of older adults across the United States and Europe take statins regularly
54 for the purpose of treating or preventing atherosclerotic cardiovascular disease (ACVD), making
55 statins one of the most prescribed medications in the developed world^{1,2}. While statins have
56 proven to be highly effective in decreasing ACVD-associated mortality, considerable
57 heterogeneity exists in terms of efficacy (i.e., lowering low density lipoprotein (LDL) cholesterol)
58³. Furthermore, statin use can give rise to a number of side effects in a subset of patients,
59 including myopathy, disrupted glucose control, and increased risk of developing type II diabetes
60 (T2D)⁴⁻⁸. Several guidelines exist for which at-risk populations should be prescribed statins and
61 at what intensity⁹. However, despite considerable progress in identifying pharmacological¹⁰ and
62 genetic factors¹¹ contributing to heterogeneity in statin response, personalized approaches to
63 statin therapy remain limited. Many times, treatment decisions are made through trial and error
64 between the clinician and patient to obtain an optimal tolerable dose¹². Avoiding this trial-and-
65 error phase through individualized analysis of genetic, physiological, and health parameters has
66 the potential to improve drug tolerance, adherence, and long-term health benefits, as well as
67 guide complementary therapies aimed at mitigating side effects.

68 Several studies have recently demonstrated a link between the gut microbiome and
69 statin use^{13,14}. Similar to other prescription drugs, statins are widely metabolized by gut bacteria
70 into secondary compounds^{15,16}. This indicates that the gut microbiome may impact statin
71 bioavailability or potency to its host, contributing to the interindividual variability in LDL response
72 seen among statin users¹⁷. Additionally, biochemical modification of statins by gut bacteria
73 could potentially contribute to side effects of the drug¹⁸. Independent of statins, the gut
74 microbiome has a well characterized role in contributing to host metabolic health through
75 regulating insulin sensitivity, blood glucose, and inflammation, hence sharing considerable
76 overlap with off-target effects of statin therapy^{19,20}.

77 Statin intake has also been implicated in shifting gut microbiome composition, where
78 primarily obese individuals taking statins were less likely to be classified into a putative gut
79 microbiome compositional state, or 'enterotype', defined by high relative abundance of
80 *Bacteroides* and a depletion of short-chain fatty acid (SCFA) producing Firmicutes taxa²¹.
81 However, contradictory findings in animal models have also been reported, where a statin
82 intervention decreased abundance of SCFA-producing taxa and, consequently, the gut
83 ecosystem's capacity to produce butyrate²².

84 Given the numerous documented interactions between the gut microbiome and statins,
85 and the established effect of the gut microbiome on metabolic health, we sought to explore the
86 potential role of the gut microbiome in modifying the effect of statins on inhibiting their target
87 enzyme 3-hydroxy-3-methylglutarate-CoA (HMG-CoA) reductase, as well as influencing the
88 negative side effects of statins on metabolic health parameters. We analyzed data from over
89 1840 deeply-phenotyped individuals with extensive medication histories, clinical laboratory
90 tests, plasma metabolomics, whole genome and stool 16S rRNA gene amplicon sequencing
91 data. We found that heterogeneity in statin on-target effects and off-target metabolic disruption
92 could be explained by variation in the composition of the gut microbiome. Overall, our results
93 suggest that, with further study and refinement, the taxonomic composition of the gut
94 microbiome may be used to inform personalized statin therapies.

95

96 **Results:**

97

98 **Cohort**

99 The study population is presented in Fig. 1A and Table S1 (see also Methods). Briefly, a total of
100 1848 adults were included in the present analysis. Individuals in this cohort were self-enrolled in
101 a now closed Scientific Wellness company (Arivale, Inc), had available plasma metabolomics
102 and clinical laboratory data, and provided detailed information on prescription medication use.

103 Of these 1848 Arivale participants, 244 were confidently identified as statin users, of which 97
104 provided detailed information on both dosage and type of statin prescribed.

105

106 **Plasma HMG is a marker of statin use and on-target effects**

107 The mechanism of action of statins is to inhibit the rate-limiting enzyme of *de novo* cholesterol
108 synthesis, HMG-CoA reductase²³. Thus, we first sought to explore whether elevated plasma
109 levels of the hydrolyzed substrate for this enzyme, HMG (measured in our broad untargeted
110 metabolomics panel), could serve as a reliable marker of statin use (Fig. 1B). Plasma HMG
111 levels were significantly higher in statin users than in non-users, consistent with our initial
112 hypothesis and the drug's well-established mechanism of action (Fig. 1C, generalized linear
113 models (GLMs) adjusted for sex, age, and BMI, Quest Diagnostics β (95% confidence interval
114 (CI)): 0.23 (0.16-0.31), $P=9.2e-10$, Lab Corp. of America (LCA) β (95% CI):0.28(0.23-0.34),
115 $P=9.8e-25$). HMG levels further showed a negative correlation with blood LDL-cholesterol
116 across two independent clinical lab vendors, but exclusively in statin users, indicating that
117 plasma HMG may not only reflect statin use but also the extent to which statins inhibit their
118 target enzyme (Fig. 1C, GLM adjusted for sex, age, and BMI, Quest β (95% CI): -0.12 (-0.19-
119 0.05), $P=0.0019$, LCA β (95% CI):-0.07(-1.2 - -0.01), $P=0.020$)).

120 The negative association between HMG and LDL-cholesterol, observed exclusively in
121 statin users, indicates that this compound may serve as a proxy for statin efficacy. However, it is
122 also possible HMG simply reflects patient adherence, where individuals who take the drug as
123 prescribed have higher HMG and lower LDL-cholesterol than those who do not. To further
124 evaluate the robustness of HMG as a marker for statin on-target effects, we explored its
125 correspondence to variable doses of statins prescribed in a subset of statin users where this
126 information was available (n=97). Different statins (atorvastatin, simvastatin, etc.) exhibit
127 different potencies and are often prescribed at variable doses. To synchronize medical practices
128 in terms of statin therapy, the American Heart Association (AHA) released guidelines for
129 adjusting statin doses across all types of statins, which cluster into one of three intensity
130 categories (low, moderate, and high) aimed at achieving desired decreases in LDL-cholesterol
131 of <30%, 30-49%, \geq 50%, respectively⁹. Based on these AHA guidelines, a daily 40mg dose of
132 Rosuvastatin would place a patient in the high intensity category, while the same dose of
133 Fluvastatin would place a patient in the low intensity group. Hence, we re-classified participants
134 into their respective therapy intensity groups based on the AHA guidelines (Fig. 1A) and
135 evaluated the associations between therapy intensity, plasma HMG, and blood LDL-cholesterol
136 levels. Therapy intensity showed a positive dose response relationship with HMG, independent
137 of sex, age, and BMI (GLM adj. β (95% CI):0.15(0.12-0.17), $P=1.1e-22$)). Consistently, an
138 inverse relationship was observed between therapy intensity and blood LDL-cholesterol (Fig.
139 1D, Ordinary Least Square (OLS) regression adjusted for sex, age, BMI and clinical lab vendor,
140 β (95% CI):-15(-18 - -12), $P=6.7e-20$)).

141 Previous large-scale pharmacogenomic studies of statin users have identified several
142 single nucleotide polymorphisms (SNPs) predisposing patients to variable responses to statin
143 therapy. To evaluate if plasma HMG captures known genetic variability in statin response, we
144 tested associations between HMG and 9 SNPs most strongly associated with statin-mediated
145 decrease in LDL-cholesterol in previous studies¹¹, using GLMs with a statin-by-genetic variant
146 interaction term while adjusting for sex, age, BMI and genetic ancestry (see Methods). Of the 9
147 SNPs tested, 2 SNPs in close linkage disequilibrium (rs445925 and rs7412 mapping to the
148 APOC1 and APOE genes, respectively, $r > 0.80$ in Caucasians) showed significant associations
149 with HMG, that were dependent on statin intake (i.e., the effect was only present in statin users,
150 $FDR < 0.05$), in the directions consistent with the previously described associations of the same
151 variants with statin response (Fig. S1, Table S2). Interestingly, running the same analysis with
152 LDL-cholesterol instead of plasma HMG as an outcome variable (both measured from the same
153 blood draw) did not reveal the same statin-dependent interactions (Table S2). In the case of

154 both rs445925 and rs7412, carrying at least one copy of the minor allele was associated with a
155 decrease in LDL-cholesterol across statin users and non-users alike, hence providing no
156 additional insight into statin-specific effects when measured cross-sectionally (Fig. S1).
157 Together, our combined analyses of statin use, statin therapy intensity and genetic variants
158 known to modify statin response indicate that HMG may provide additional insight into statin on-
159 target effects, not captured by a snapshot measurement of LDL-cholesterol.

160

161 ***Statin use is associated with subtle differences in the gut microbiome***

162 Given the previously established associations between the gut microbiome and statin use, we
163 next investigated whether statin intake is associated with changes in gut microbiome
164 composition. Consistent with previous research, statin use showed a significant association with
165 interindividual variability in gut microbiome composition, using the Bray-Curtis dissimilarity
166 metric (PERMANOVA unadjusted model $R^2=0.0025$, $P=0.00067$, model adjusted for
167 microbiome vendor, sex, age, and BMI, $R^2=0.0021$, $P=0.0017$) and Weighted UniFrac
168 (unadjusted model $R^2=0.0017$, $P=0.031$, model adjusted for the same covariates as the Bray-
169 Curtis model, $R^2=0.0013$, $P=0.065$) (Fig. 2A, Fig. S1). Statin intake was further associated with
170 a modest decrease in one of the two α -diversity metrics calculated (OLS regression models
171 predicting Shannon diversity adjusted for the same covariates as PERMANOVA, adj. β (95%
172 CI): -0.095 (-0.16 - -0.028), $P=0.0051$) (Fig. 2B). When looking at specific statin therapy intensity
173 for a subset of participants where this information was available, there was no monotonic dose-
174 response relationship with gut α -diversity, with only individuals receiving moderate intensity
175 statin therapy demonstrating a significant decrease in measures of gut α -diversity relative to
176 non-users (Fig. 2C, Fig. S1).

177

178 ***Gut microbiome α - and β -diversity correlate with markers of statin efficacy***

179 Next, we investigated whether gut microbiome beta-diversity may explain interindividual
180 heterogeneity in response to statin therapy. Using HMG as a proxy for statin inhibition of its
181 target enzyme, we modelled correspondence between statin on-target effects and interindividual
182 variability in gut microbiome β -diversity using PERMANOVA and including a statin-by-HMG
183 interaction term. The interaction terms had permutation-based p-values of 0.0070 ($R^2=0.0017$)
184 and 0.0013 ($R^2=0.0032$) for Bray-Curtis and Weighted UniFrac metrics, respectively, which
185 remained significant after adjusting for microbiome vendor, BMI, sex, and age (Fig. 2A, Fig. S1).
186 These results indicate that HMG correspondence to gut microbiome composition is dependent
187 on statin intake, similar to the HMG-SNP associations reported earlier (Fig. S1). Very similar
188 patterns were observed for gut α -diversity, where, once again, the association between our
189 proxy for statin efficacy, HMG, and gut α -diversity was dependent on statin intake (Figure 2D).
190 Plotting the association between gut α -diversity and HMG stratified by statin use revealed that,
191 among statin users, higher α -diversity corresponded to lower plasma HMG levels, indicating
192 decreased on-target effects of the drug in individuals with more diverse microbiomes (Fig. 2D).
193 The negative association between HMG and α -diversity in statin users was also orthogonal to
194 genetic variants predisposing individuals to variable statin responses. Running a stepwise
195 forward regression model predicting HMG levels using the 9 SNPs previously associated with
196 statin response explained an additional 3.2% of variance in HMG, on top of age (i.e. the base
197 model). Including observed ASVs as a measure of gut diversity in the model in addition to age
198 and the chosen SNPs increased the percent variance explained by an additional 3.9%
199 (complete model $R^2=0.185$).

200 To further exclude the possibility that individuals with higher α -diversity are generally
201 healthier and simply prescribed less potent statin therapies to begin with, thus leading to lower
202 levels of HMG, we further adjusted our models for dosage intensity in the subset of participants
203 with microbiome data where this information was available ($n=75$). In this smaller group of
204 individuals, associations between gut α -diversity and HMG were not impacted by correcting for

205 statin intensity (Fig. 2E & Fig. S2). Similar results were observed when investigating statin
206 dependent associations between LDL-cholesterol and gut α -diversity, although to a weaker
207 extent (OLS models predicting LDL-cholesterol adjusted for clinical lab and microbiome
208 vendors, sex, age, and BMI, statin-by-Shannon diversity interaction term β (95% CI):12.2(2.5-
209 22.0), $P=0.014$, statin-by-Observed Amplicon Sequence Variants (ASVs) interaction term β (95%
210 CI):0.042(0.00086-0.084), $P=0.044$, Fig. S2). A weaker interaction effect with LDL cholesterol is
211 to be expected, given the cross-sectional nature of our study and our inability to capture the
212 percent decrease in LDL-cholesterol from baseline following the initiation of statin treatment,
213 one of the most common and direct measures of statin effectiveness^{3,17}.

214 As another measure of gut microbiome correspondence to statin response, we tested
215 the association between measures of gut α -diversity and the likelihood of having reached pre-
216 defined target LDL-cholesterol levels for statin users (<70mg/dL and <100mg/dL). These are
217 clinically relevant targets, as clinicians are recommended to adjust dosage and type of statin
218 prescribed to reach these levels of LDL-cholesterol depending on the presence of specific
219 ASCVD risk factors in their patients²⁴. Both Shannon diversity and Observed ASVs showed
220 negative associations with likelihood of having reached target LDL-levels among statin users
221 (Multivariable logistic regression adjusted for clinical lab vendor, sex, age, BMI, and T2D status
222 [a common criteria, in combination with one or more CVD risk factors, where more aggressive
223 LDL-lowering therapy is pursued]): Odds Ratios (OR) ranging from 0.60-0.69, Table 1).
224 Together, these results indicate that gut microbiome composition can explain a significant
225 proportion of variability in statin on-target effects in a generally healthy community-dwelling
226 population.

227 228 **Statin-associated changes in on- and off-target effects are dependent on microbiome** 229 **compositional states**

230 Prior work on the gut microbiome and statins has relied on clustering individuals into
231 microbiome-based compositional states called 'enterotypes'^{25,26}. A recent study revealed that
232 statin intake among obese individuals was associated with lower prevalence of the *Bacteroides*
233 2 (*Bac.2*) enterotype, which is generally considered to be less healthy than other broad
234 enterotype groupings common to cohorts in the United States and Europe²¹. To evaluate the
235 extent to which these coarse ecological groupings might help explain interindividual variation in
236 statin on- and off-target effects, we stratified our cohort into enterotypes. Using a previously
237 established method for enterotype identification, Dirichlet multinomial mixture (DMM) modeling
238²⁷, the participants in the Arivale cohort separated optimally into four groups, according to the
239 Bayesian Information Criterion (BIC), consistent with some, but not all, previous human gut
240 microbiome studies (*Bacteroides* 1 (*Bac.1*), *Bac.2*, *Ruminococcaceae* (*Rum.*), and *Prevotella*
241 (*Prev.*) clusters)^{21,26-28} (Fig. 3A, Fig. S2). The four enterotypes identified showed very similar
242 characteristics to those described previously in European cohorts, with two *Bacteroides*-
243 dominated enterotypes (*Bac.1* and *Bac.2*), with the *Bac.2* enterotype being further characterized
244 by decreased α -diversity and a depletion of SCFA-producing commensals like *Faecalibacterium*
245 and *Subdoligranulum* (Fig. 3B, Fig. S2). The *Rum.* enterotype was enriched for taxa primarily
246 from the Firmicutes phylum, as well as *Akkermansia* (Fig. S2, Data S1), consistent with previous
247 findings²⁵. The *Prev.* enterotype was the smallest in size and characterized by high relative
248 abundance of the *Prevotella* genus (Fig. 3D, Data S1).

249 We first attempted to replicate previous findings²¹ documenting an observed lower
250 prevalence of the *Bac.2* enterotype in obese individuals taking statins. Consistent with previous
251 results, obesity itself was associated with a higher likelihood of being assigned to the *Bac.2*
252 enterotype (Multivariable logistic regression adjusted for microbiome vendor, sex, and age,
253 OR(95%CI): 1.8 (1.4-2.3), $P=5.0e-5$). However, contrary to the original findings, we actually
254 observed a higher prevalence of the *Bac.2* enterotype among statin users compared to non-
255 users, particularly among obese individuals (Fig. 3E). This association among obese individuals

256 was further confirmed using multivariable logistic regression adjusting for sex, age, and
257 microbiome vendor (OR (95%CI): 2.1 (1.2-3.7), $P=0.013$, $n=462$).

258 We next set out to explore whether an individual's enterotype was associated with their
259 response to statin therapy. Focusing on statin on-target effects, we observed a significant
260 enterotype-by-statin interaction when modeling blood HMG levels ($P=0.044$, unadjusted
261 analysis of variance (ANOVA), $P=0.034$, analysis of covariance (ANCOVA) adjusted for
262 microbiome vendor, clinical lab vendor, sex, age, and BMI). Stratifying the cohort by enterotypes
263 and comparing statin users to non-users revealed statin use within the *Bac.2* enterotype
264 correlated with the highest HMG levels (37% mean increase relative to non-users), followed by
265 the *Bac.1* (24%) and *Rum.* enterotypes (18%). Interestingly, individuals with a *Prev.* enterotype
266 showed no significant difference in HMG between statin users and non-users, although our
267 sample size for this enterotype was small and thus this result needs to be interpreted with
268 caution (Fig. 3F). Similar results were obtained when evaluating statin-by-enterotype interaction
269 effects on LDL-cholesterol levels ($P=0.021$, unadjusted ANOVA, $P=0.0032$, ANCOVA adjusted
270 for same covariates as HMG models), with statin users with a *Bac.2* enterotype demonstrating
271 lowest LDL-cholesterol levels (-33%) relative to non-users within the same enterotype (Fig. S3).
272 Statin users who were assigned the *Bac.2* enterotype were also two to four-times more likely to
273 have reached common LDL-cholesterol target levels for statin-users at higher risk for ASCVD
274 (Table 1). Collectively, these results suggest that microbiome enterotypes may reflect the extent
275 to which statins inhibit HMG-CoA reductase and reduce LDL-cholesterol levels across
276 individuals.

277 Statin use has previously been associated with disrupted glucose control and increased
278 risk of developing T2D in a subset of patients^{5,7,29}. Given the known role of the gut microbiome
279 in contributing to metabolic homeostasis, and the variable metabolic profiles previously
280 observed across different microbiome enterotypes^{21,30}, we investigated whether enterotypes
281 may modify the association between statin use and markers of insulin resistance. Focusing
282 initially on Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)^{31,32}, we tested for
283 an enterotype-by-statin interaction effect while adjusting for microbiome vendor, clinical lab
284 vendor, sex, age, BMI, LDL-cholesterol, and plasma HMG using ANCOVA. Individuals showed
285 variable responses to statin therapy based on their microbiome enterotype, with *Bac.2*
286 individuals on statins demonstrating the highest levels of HOMA-IR relative to non-statin users,
287 while *Rum.* individuals showed no significant difference in HOMA-IR between statin users and
288 non-users (ANOVA unadjusted interaction term $P=0.0037$, ANCOVA covariate adjusted
289 Interaction term $P=0.0495$, Fig. 3G, Table 2). It is worth noting that in the subset of participants
290 where dosage intensity information was available, all three intensities (low, moderate, high)
291 were associated with a comparable increase in HOMA-IR, suggesting that differences in therapy
292 intensity are likely not the main driver behind the observed statin-enterotype interaction (Fig.
293 S2).

294 We next expanded our analysis into additional markers of metabolic health, including
295 fasting insulin and blood glucose, as well as glycated hemoglobin A1c. There was a significant
296 enterotype-by-statin interaction across all tested metabolic parameters, which remained
297 significant after adjusting for covariates across all markers other than insulin (Table 1, Fig. S3).
298 As individuals with T2D are often recommended to take statins, we further adjusted all models
299 for T2D status in participants where this information was available ($N=1691$, T2D $n=66$), which
300 did not change the significance of enterotype-by-statin interaction effects observed (Table 2).
301 Collectively, these results suggest that gut microbiome composition may modify how statins
302 influence off-target physiology, particularly glucose homeostasis.

303 Discussion

304 There is considerable heterogeneity in response to statin therapy among individuals, both in
305 terms of on-target effects (lowering LDL-cholesterol) and likelihood of experiencing unwanted
306

307 side-effects^{3,7,29}. Herein, we report that variation in gut microbiome taxonomic composition can
308 explain interindividual variability in statin responses. The main findings of our analyses are as
309 follows: 1) HMG measured in plasma is a robust marker of both statin use and statin on-target
310 effects, which also reflects known genetic variability in statin responses; 2) Gut α -diversity
311 negatively correlates with HMG exclusively in statin users, independent of dose intensity and
312 genetic predisposition, indicating a more diverse microbiome may interfere with statin on-target
313 effects; 3) Enterotype analysis further confirms similar patterns of microbiome modification of
314 statin response, with the *Bacteroides* dominant, α -diversity-depleted *Bac.2* enterotype showing
315 the highest plasma HMG and lowest LDL-cholesterol levels among statin users; and 4) Of the
316 four enterotypes identified, individuals with the *Bac.2* followed by *Bac.1* enterotypes experience
317 greatest disruption to glucose control when on statins, while the Firmicutes rich *Rum.* enterotype
318 appears most protective, indicating variable risk of statin-mediated metabolic side effects based
319 on gut microbiome composition. Collectively, our findings indicate that the gut microbiome
320 influences statin actions. With further refinement, knowledge of these effects may inform statin
321 therapy guidelines and help personalize ASCVD treatment.

322 To the best of our knowledge, measuring HMG in large observational studies for the
323 purpose of exploring statin-mediated effects has not been previously proposed. The conversion
324 of HMG-CoA to HMG is dependent on the hydrolysis of the thioester bond linking HMG to its
325 Coenzyme-A moiety, which has been previously shown to be facilitated by at least one known
326 thioesterase (peroxisomal acyl-CoA thioesterase 2)³³. Relatively little is known about the
327 accumulation of HMG with statin therapy and the pathways involved, which warrants further
328 research. Nevertheless, there are several advantages for including HMG along with LDL-
329 cholesterol measurements when evaluating statin effects. For one, given the limitations of a
330 cross-sectional study design like ours, HMG may provide more time-invariant insight into statin
331 efficacy, as opposed to LDL-cholesterol, which would require knowledge of pre-statin
332 cholesterol levels to calculate the percent decrease in LDL over time³. This seemed to be the
333 case in our genetics analysis, where cross-sectional measurements of plasma HMG were able
334 to capture previously reported genetic variability in statin response while LDL-cholesterol
335 measurements from the same blood draw were less sensitive. In addition, plasma HMG could
336 prove useful when evaluating statin off-target effects on metabolic health parameters, where
337 statistical models could be adjusted for HMG to account for variability in statin on-target effects,
338 as was done in our analysis exploring markers of insulin resistance.

339 An intriguing finding in the present analysis was an absence of statin-associated
340 metabolic disruption in individuals with a *Rum.* enterotype (Fig. 3G, Fig. S3). Statin use in this
341 group was still associated with increased plasma HMG and decreased LDL-cholesterol levels
342 (Fig. 3F, Fig. S3), indicating that patients with this microbiome composition type may benefit
343 from statin therapy without an increased risk of unwanted metabolic complications. There are
344 several possible explanations for this observation. For example, the *Rum.* enterotype is
345 enriched in the genus *Akkermansia*, as well as several butyrate-producing taxa, which are
346 known to positively impact host metabolism through multiple mechanisms (Table S2, Fig. S2)
347^{25,34}, potentially serving as a buffer against statin off-target effects on glucose homeostasis. In
348 addition, statins and other prescription drugs have been previously shown to be most readily
349 metabolized by species within the *Bacteroides* genus, of which the *Rum.* enterotype is most
350 depleted. The lower degree of drug metabolism by Firmicutes taxa comprising the *Rum.*
351 enterotype may therefore be potentially protective from statin off-target effects. Consistently,
352 both *Bacteroides* rich *Bac.1* and *Bac.2* enterotypes showed highest levels of markers of insulin
353 resistance with statin use.

354 Statin use in individuals with the *Bac.2* enterotype was associated with the strongest on-
355 target effects (i.e., high plasma HMG and low LDL-cholesterol levels) but also greatest
356 metabolic disruption among all four enterotypes (Fig. 3F-G, Fig. S3). This is consistent with
357 previous observational studies that have identified an association between the magnitude of

358 decrease in LDL-cholesterol with statin use and risk of developing T2D (i.e., the greater the
359 percent decrease in LDL-cholesterol with statin therapy, the higher the risk of new onset T2D)
360 ^{6,35}. One possible mechanism behind the reported association is the previously mentioned ability
361 of *Bacteroides* species to metabolize prescription drugs, including statins ¹⁵. *Bacteroides*
362 dominance within both the *Bac.1* and *Bac.2* enterotypes may modify drug activity, impacting
363 both potency and potential side effects. Paired with depletion of several major butyrate-
364 producing taxa within the *Bac.2* enterotype (Fig. 3D, Fig. S1, Data S1), this bacterial
365 composition may put patients at particularly high risk of metabolic complications. If this were
366 indeed the case, individuals with a *Bac.2* enterotype could benefit most from lower intensity
367 therapy, which might still achieve the desired percent decrease in LDL-cholesterol while
368 mitigating potential metabolic disruptions. Complementary pro- or prebiotic interventions could
369 also be potentially pursued in these individuals. However, further experimental work is needed
370 to fully elucidate the microbiome-statin interactions that may be driving the reported
371 associations.

372 While our present investigation identified very similar enterotype structure to a previous
373 study on statin use and the gut microbiome by Veiera-Silva *et al.* ²¹, our analysis also showed
374 conflicting results in terms of prevalence of the putatively dysbiotic *Bac.2* enterotype among
375 obese statin users (Fig. 3E). One possible explanation for this discrepancy is that in the original
376 study individuals were primarily prescribed Simvastatin (48% of statin users), which is a lower
377 intensity HMG-CoA reductase inhibitor than the most commonly prescribed Atorvastatin in our
378 cohort (53% of all statin users). The different statin types may have a different impact on the gut
379 microbiome. Alternatively, the studied population of obese statin users in the original study by
380 Veiera-Silva *et al.* may have been healthier and hence prescribed lower intensity therapies than
381 the cohort presented in this study, resulting in these variable findings. Finally, additional
382 confounding variables may be responsible for the observed shifts in enterotype proportions
383 among obese statin users across both studies. It's worth noting that, while the prior study ²¹
384 focused on how statins might influence the composition of the microbiome, our study focused on
385 how the composition of the microbiome impacts the on- and off-target effects of statins in the
386 host. Our analyses indicate that statins have a detectable, but very weak effect on the
387 composition of the gut microbiome, while the gut microbiome appears to have a more sizable
388 impact on host responses to statin treatment.

389 Growing evidence suggests a bidirectional interaction between prescription medication
390 use and the gut microbiome, which may inform drug treatment for hundreds of millions of people
391 worldwide. Here we present a proof-of-concept study on how gut microbiome composition may
392 be used to stratify patients to inform statin therapy. As our understanding of microbe-drug
393 interactions deepens, gut microbiome modification and monitoring hold promise for informing
394 pharmacological treatment optimization.

395
396
397
398
399
400
401
402
403
404
405
406
407
408

409 **Methods:**

410 **Cohort:** The Arivale cohort consists of adults (18+ years old) who self-enrolled in a now closed
411 lifestyle intervention program (Arivale, Inc. 2015-2019)³⁶⁻³⁹. The lifestyle intervention was
412 designed to improve a number of key outcomes based on longitudinal profiling of clinical
413 biomarkers and individualized coaching. For the present study, only individuals who filled out
414 medication questionnaires, and/or reported their prescription medication information directly to
415 their coach during a 1-on-1 session, were included. Participants further had to have available
416 fasting plasma metabolomics and clinical laboratory test data (N=1848). Only baseline
417 measurements and corresponding medication doses at the start of the program were
418 considered, i.e. before any lifestyle interventions were recommended. Of the 1848 participants
419 originally included, after excluding individuals who reported taking antibiotics in that last 3
420 months, 1512 had available stool 16S rRNA gene sequencing data. Similar to the larger Arivale
421 population, the majority of participants of this study were residents of Washington and California
422 when in the program. Although the cohort tends to be leaner than the general U.S. population
423 (prevalence of obesity is 31% relative to the national prevalence of 42%⁴⁰), it is representative of
424 the populations in the states where the majority of the participants were located. The cohort is
425 further predominantly female (63%) and is skewed towards Caucasians (81%). Additional
426 demographic information on the cohort is provided in Table S1.

427 **Microbiome Analysis**

428 Stool samples in the Arivale cohort were collected using kits developed by two
429 microbiome vendors (DNAGenotek or Second Genome), and processed as described
430 previously^{37,41}. Briefly, stool sample collection kits with proprietary chemical DNA stabilizers to
431 maintain DNA integrity at ambient temperatures were shipped directly to participants' homes
432 and then shipped back to the vendors. Gut microbiome sequencing data in the form of FASTQ
433 files were then obtained from the vendors on the basis of either the 300-bp paired-end MiSeq
434 profiling of the 16S V3 + V4 region (DNAGenotek) or 250-bp paired-end MiSeq profiling of the
435 16S V4 region (Second Genome). Downstream analysis was performed using a denoise
436 workflow from mbtools (<https://github.com/gibbons-lab/mbtools>) that wraps functions from
437 DADA2. DADA2⁴² error models were first trained separately for each sequencing run and
438 subsequently used to obtain amplicon sequence variants (ASVs) for each sample. Next,
439 chimera removal was performed using the *de novo* DADA2 algorithm, which removed ~17% of
440 all reads. Taxonomy assignment was performed using the RDP classifier with the SILVA
441 database (version 132). In summary, 99% of the reads could be classified to the family level,
442 89% to the genus level and 32% to the species level. Sequence variants were aligned to each
443 other using DECIPHER⁴³ and multiple sequence alignment was trimmed by removing each
444 position that consisted of more than 50% gaps. The resulting core alignment was then used to
445 reconstruct a phylogenetic tree using FastTree⁴⁴. Downstream gut microbiome analysis was
446 conducted using the *Phyloseq* Package in R (v 3.6)⁴⁵. Gut microbiome samples were first
447 rarefied to an even sampling depth of 25596 reads, corresponding to the minimum number of
448 reads per sample in the dataset. Bray-Curtis⁴⁶ and Weighted UniFrac⁴⁷ dissimilarity matrices
449 were calculated at the genus-level using the *Phyloseq* package. Alpha-diversity measures were
450 calculated at the ASV-level using the *Phyloseq* Package. Enterotype analysis was performed
451 using Dirichlet Multinomial Mixture (DMM) modeling on the rarefied genus-level count data, as
452 previously described²⁷. For selecting the optimal number of DMM groups in our cohort (i.e.
453 enterotypes), we used the Bayesian information criterion (BIC) (Fig.S2).

454 However, BIC as a model penalization metric is not without limitations and tends to err
455 on the side of underfitting (i.e., estimating a smaller number of clusters). The Laplace
456 approximation for model penalization²⁷, on the other hand, did not identify an optimal number of
457 clusters in this particular dataset (out to a maximal number of eight clusters tested), indicating
458 limited statistical evidence for a small number of coarse-grained compositional states within our
459 cohort (Fig. S2). Nevertheless, the main enterotype groupings tend to be relatively consistent

460 from study-to-study in large U.S. and European populations, even if the statistical evidence for
461 such states is somewhat limited²⁶. Given that the four BIC-identified enterotypes in our cohort
462 show strikingly similar taxonomic signatures to those identified in prior work on statins²¹, we
463 moved forward with an analysis of these compositional states and how they relate to statin
464 response.

465 **Clinical Laboratory Tests**

466 Blood draws for all assays were performed by trained phlebotomists at LabCorp (n=1309) or
467 Quest (n=553) service centers, and assaying was performed in CLIA-certified laboratory
468 facilities by the vendors. Blood samples for clinical laboratory tests were obtained at the same
469 time as the metabolomics blood draw, and only the baseline sample prior to any lifestyle
470 coaching intervention was considered. Prior to the blood draw, Arivale participants were advised
471 to avoid alcohol, vigorous exercise, aspartame, and monosodium glutamate for 24 hours, and to
472 begin fasting 12 hours in advance.

473 **Plasma Metabolomics**

474 Plasma HMG was measured as part of the metabolomics data generated by Metabolon, Inc., on
475 the same blood draws as clinical laboratory tests. Raw metabolomics data was normalized as
476 described previously^{36,37}. Values were median scaled within each batch, such that the median
477 value for each metabolite was 1. To adjust for possible batch effects, further normalization
478 across batches was performed by dividing the median-scaled value of each metabolite by the
479 corresponding average value for the same metabolite in technical control samples processed in
480 the same batch. The same technical control samples were used to ensure the comparability of
481 abundance estimates obtained across batches.

482 **Genetics Analysis**

483 Participant DNA was extracted from whole blood and, following quality control and purification,
484 as needed, underwent 150 PE whole genome sequencing (WGS) using Illumina's HiSeq X at
485 30x coverage as described previously⁴⁸. Variant calling was performed by the vendor using the
486 pipeline that follows GATK's Best Practices, using Haplotype Caller and hg19 build as the
487 reference genome. A total of 1747 participants (~94% of the present cohort) had available WGS
488 data and were used in the present analysis. Following extensive quality control and assurance,
489 genetic ancestry was calculated as principal components (PCs) using a set of ~100,000
490 ancestry-informative SNP markers as described previously⁴⁹. SNPs chosen for testing
491 associations with HMG were based on prior studies investigating genetic predisposition to statin
492 efficacy defined as percent decrease in LDL-cholesterol from baseline, and included the
493 following variants: rs10455872, rs2199936, rs2900478, rs4420638, rs445925, rs5908,
494 rs646776, rs7412, and rs8014194¹¹. To model the association between SNPs and HMG in
495 statin users, individuals homozygous and heterozygous for the minor allele were grouped
496 together. Statistical analysis was performed on each SNP individually using GLM with a Gamma
497 distribution and a log-link function within the statsmodels module in Python, with HMG as the
498 dependent variable and a statin-by-SNP interaction term. The interaction term tests for a
499 significant association between HMG and statin use, that is modified by the SNP of interest (i.e.
500 the effect of statins on HMG are variable based on the genetic variant). Models were further
501 adjusted for sex, age, BMI and the first 7 ancestry PCs. Ordinary Least Square (OLS)
502 regression models with the same covariates and interaction term were also run with LDL-
503 cholesterol as the dependent variable. Type-1 error was controlled using the Benjamini-
504 Hochberg method (FDR<0.05).

505 **Statistical Analysis**

506 Depending on the statistical approach, analysis was conducted using either R (v 3.6) or Python
507 (v 3.7). Of the 1848 participants included in our study, 73 had missing data on sex and age, 66
508 on BMI, and 81 on HMG. These missing values were imputed using plasma metabolomics data
509 and the K nearest neighbor algorithm implemented through the sklearn.impute module in
510 Python. The associations of plasma HMG levels with LDL-cholesterol, statin intensity, and

511 measures of gut alpha-diversity were all tested using Generalized Linear Models (GLM) with a
512 Gamma distribution and a log-link function within the statsmodels module in Python, with HMG
513 as the dependent variable. OLS regression (Python) was used whenever LDL-cholesterol or
514 measures of gut alpha-diversity were the dependent variables. Testing for associations between
515 variables and interindividual variability in gut microbiome composition was conducted using
516 permutational multivariate analysis of variance (PERMANOVA) through the *Adonis* package in
517 R using both the genus-level Bray-Curtis and Weighted UniFrac dissimilarity matrices. The
518 number of permutations to obtain P-values was set to 3000.

519 For assessing dose-response relationships between HMG/LDL-cholesterol and dosage
520 intensity (Fig. 1D), dosage was recoded into an ordinal variable (0(none/no statins), 1(low),
521 2(moderate), 3(high)), and the significance of the β -coefficient for that variable from covariate
522 adjusted models predicting either HMG(GLM adjusted for sex, age, and BMI) or LDL-
523 cholesterol (OLS adjusted for sex, age, BMI, and clinical lab vendor) was reported. Wherever
524 associations were visualized using box plots or scatter plots, the residuals (values adjusted for
525 covariates from either GLM or OLS models) were plotted instead of the original values. For
526 comparing the differences in prevalence of the four enterotypes among statin users and non-
527 users, the χ^2 test was performed using the *chisq.test* function in R. When evaluating the
528 association between obesity and *Bac.2* enterotype, as well as statin use and *Bac.2* enterotype
529 among obese participants, multivariable logistic regression models were generated through the
530 statsmodels module in Python with *Bac.2* membership (versus all other enterotypes) as the
531 dependent variable.

532 When testing for significant enterotype-by-statin interactions, HMG and metabolic
533 parameters (blood glucose, blood insulin, HOMA-IR, and HbA1c) were log transformed prior to
534 fitting the models. Analysis of Variance (ANOVA) or covariance (ANCOVA) models were then
535 used to test for significant interactions (ANOVA (*measure ~*
536 *statin_use+enterotype+statin_use*enterotype*) for unadjusted models and ANCOVA
537 (*measure~covariate 1+covariate 2+... covariateX+ statin_use+ enterotype+*
538 *statin_use*enterotype*) for covariate adjusted models)) using the statsmodels module in Python.
539 If a significant interaction was present, post-hoc comparisons were performed between statin
540 users and non-users within each enterotype on the covariate adjusted values (residuals) using
541 two-sample t-tests, with Bonferroni corrected $P<0.05$ considered statistically significant.

542
543 **Acknowledgments:** We kindly thank Arivale participants who consented to let their deidentified
544 data be used for research purposes. This work was supported by the M.J. Murdock Charitable
545 Trust (to L.H. and N.D.P.), and Arivale. S.M.G., and C.D. were supported by a Washington
546 Research Foundation Distinguished Investigator Award and by start-up funds from the Institute
547 for Systems Biology. Further support came from the National Academy of Medicine Catalyst
548 Award (to E.S.O, S.M.G., and L.H.) and a National Institutes of Health (NIH) grant (no.
549 U19AG023122) awarded by the National Institute on Aging (NIA) (to P.S., E.S.O, and N.R.).

550 **Author contributions:** T.W., N.D.P., N.R., A.T.M., and S.M.G. conceptualized the study. T.W.,
551 S.K., J.C.L., P.S., E.S.O, L.H., N.D.P., N.R., A.T.M. and S.M.G. participated in the study design.
552 T.W., S.K., C.D., M.C. performed data analysis. A.T.M., S.K., M.C., and J.C.L. managed the
553 logistics of data collection and integration. T.W., N.R., A.T.M. and S.M.G. were the primary
554 authors of the paper, with contributions from all others. All authors read and approved the final
555 manuscript.

556 **Competing interests:** The authors declare no competing interests.

557 **Data and materials availability:** Code used to analyze 16S rRNA gene amplicon sequencing
558 data can be found at <https://github.com/gibbons-lab/mbtools> while code used to run the
559 statistical analysis is available at https://github.com/PriceLab/Statins_microbiome_project.
560 Qualified researchers can access the full Arivale deidentified dataset supporting the findings in
561 this study for research purposes through signing a Data Use Agreement (DUA). Inquiries to

562 access the data can be made at data-access@isbscience.org and will be responded to within 7
563 business days.

564
565

566 **References:**

567

568. P. Byrne, J. Cullinan, C. Murphy, S. M. Smith, Cross-sectional analysis of the prevalence and
569 predictors of statin utilisation in Ireland with a focus on primary prevention of cardiovascular
570 disease. *BMJ Open*. **8**, e018524 (2018).
571. J. A. Salami, H. Warraich, J. Valero-Elizondo, E. S. Spatz, N. R. Desai, J. S. Rana, S. S. Virani,
572 R. Blankstein, A. Khera, M. J. Blaha, R. S. Blumenthal, D. Lloyd-Jones, K. Nasir, National
573 Trends in Statin Use and Expenditures in the US Adult Population From 2002 to 2013: Insights
574 From the Medical Expenditure Panel Survey. *JAMA Cardiol*. **2**, 56–65 (2017).
575. P. M. Ridker, S. Mora, L. Rose, Percent reduction in LDL cholesterol following high-intensity
576 statin therapy: potential implications for guidelines and for the prescription of emerging lipid-
577 lowering agents. *European Heart Journal*. **37** (2016), pp. 1373–1379.
578. P. M. Ridker, E. Danielson, F. A. H. Fonseca, J. Genest, A. M. Gotto Jr, J. J. P. Kastelein, W.
579 Koenig, P. Libby, A. J. Lorenzatti, J. G. MacFadyen, B. G. Nordestgaard, J. Shepherd, J. T.
580 Willerson, R. J. Glynn, JUPITER Study Group, Rosuvastatin to prevent vascular events in men
581 and women with elevated C-reactive protein. *N. Engl. J. Med*. **359**, 2195–2207 (2008).
582. A. A. Carter, T. Gomes, X. Camacho, D. N. Juurlink, B. R. Shah, M. M. Mamdani, Risk of
583 incident diabetes among patients treated with statins: population based study. *BMJ*. **346**, f2610
584 (2013).
585. S. Wang, R. Cai, Y. Yuan, Z. Varghese, J. Moorhead, X. Z. Ruan, Association between
586 reductions in low-density lipoprotein cholesterol with statin therapy and the risk of new-onset
587 diabetes: a meta-analysis. *Sci. Rep*. **7**, 39982 (2017).
588. J. C. Engeda, A. Stackhouse, M. White, W. D. Rosamond, S. K. Lhachimi, J. L. Lund, T. C.
589 Keyserling, C. L. Avery, Evidence of heterogeneity in statin-associated type 2 diabetes mellitus
590 risk: A meta-analysis of randomized controlled trials and observational studies. *Diabetes*
591 *Research and Clinical Practice*. **151** (2019), pp. 96–105.
592. E. Bruckert, G. Hayem, S. Dejager, C. Yau, B. Bégaud, Mild to moderate muscular symptoms
593 with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study. *Cardiovasc. Drugs*
594 *Ther*. **19**, 403–414 (2005).
595. D. K. Arnett, R. S. Blumenthal, M. A. Albert, A. B. Buroker, Z. D. Goldberger, E. J. Hahn, C. D.
596 Himmelfarb, A. Khera, D. Lloyd-Jones, J. W. McEvoy, E. D. Michos, M. D. Miedema, D. Muñoz,
597 S. C. Smith Jr, S. S. Virani, K. A. Williams Sr, J. Yeboah, B. Ziaeian, 2019 ACC/AHA Guideline
598 on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the
599 American College of Cardiology/American Heart Association Task Force on Clinical Practice
600 Guidelines. *J. Am. Coll. Cardiol*. **74**, 1376–1414 (2019).
601. B. S. Wiggins, J. J. Saseen, R. L. Page 2nd, B. N. Reed, K. Sneed, J. B. Kostis, D. Lanfear, S.
602 Virani, P. B. Morris, American Heart Association Clinical Pharmacology Committee of the

- 603 Council on Clinical Cardiology; Council on Hypertension; Council on Quality of Care and
604 Outcomes Research; and Council on Functional Genomics and Translational Biology,
605 Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins
606 and Select Agents Used in Patients With Cardiovascular Disease: A Scientific Statement From
607 the American Heart Association. *Circulation*. **134**, e468–e495 (2016).
- 608 1. I. Postmus, S. Trompet, H. A. Deshmukh, M. R. Barnes, X. Li, H. R. Warren, D. I. Chasman, K.
609 Zhou, B. J. Arsenault, L. A. Donnelly, K. L. Wiggins, C. L. Avery, P. Griffin, Q. Feng, K. D.
610 Taylor, G. Li, D. S. Evans, A. V. Smith, C. E. de Keyser, A. D. Johnson, A. J. M. de Craen, D. J.
611 Stott, B. M. Buckley, I. Ford, R. G. J. Westendorp, P. E. Slagboom, N. Sattar, P. B. Munroe, P.
612 Sever, N. Poulter, A. Stanton, D. C. Shields, E. O'Brien, S. Shaw-Hawkins, Y.-D. I. Chen, D. A.
613 Nickerson, J. D. Smith, M. P. Dubé, S. M. Boekholdt, G. K. Hovingh, J. J. P. Kastelein, P. M.
614 McKeigue, J. Betteridge, A. Neil, P. N. Durrington, A. Doney, F. Carr, A. Morris, M. I. McCarthy,
615 L. Groop, E. Ahlqvist, Welcome Trust Case Control Consortium, J. C. Bis, K. Rice, N. L. Smith,
616 T. Lumley, E. A. Whitsel, T. Stürmer, E. Boerwinkle, J. S. Ngwa, C. J. O'Donnell, R. S. Vasan,
617 W.-Q. Wei, R. A. Wilke, C.-T. Liu, F. Sun, X. Guo, S. R. Heckbert, W. Post, N. Sotoodehnia, A.
618 M. Arnold, J. M. Stafford, J. Ding, D. M. Herrington, S. B. Kritchevsky, G. Eiriksdottir, L. J.
619 Launer, T. B. Harris, A. Y. Chu, F. Giulianini, J. G. MacFadyen, B. J. Barratt, F. Nyberg, B. H.
620 Stricker, A. G. Uitterlinden, A. Hofman, F. Rivadeneira, V. Emilsson, O. H. Franco, P. M. Ridker,
621 V. Gudnason, Y. Liu, J. C. Denny, C. M. Ballantyne, J. I. Rotter, L. Adrienne Cupples, B. M.
622 Psaty, C. N. A. Palmer, J.-C. Tardif, H. M. Colhoun, G. Hitman, R. M. Krauss, J. Wouter
623 Jukema, M. J. Caulfield, Pharmacogenetic meta-analysis of genome-wide association studies of
624 LDL cholesterol response to statins. *Nat. Commun.* **5**, 5068 (2014).
- 625 2. C. Reiter-Brennan, A. D. Osei, S. M. Iftexhar Uddin, O. A. Orimoloye, O. H. Obisesan, M.
626 Mirbolouk, M. J. Blaha, O. Dzaye, ACC/AHA lipid guidelines: Personalized care to prevent
627 cardiovascular disease. *Cleve. Clin. J. Med.* **87**, 231–239 (2020).
- 628 3. J. Kim, H. Lee, J. An, Y. Song, C.-K. Lee, K. Kim, H. Kong, Alterations in Gut Microbiota by
629 Statin Therapy and Possible Intermediate Effects on Hyperglycemia and Hyperlipidemia. *Front.*
630 *Microbiol.* **10**, 1947 (2019).
- 631 4. R. Kaddurah-Daouk, R. A. Baillie, H. Zhu, Z.-B. Zeng, M. M. Wiest, U. T. Nguyen, K.
632 Wojnoonski, S. M. Watkins, M. Trupp, R. M. Krauss, Enteric microbiome metabolites correlate
633 with response to simvastatin treatment. *PLoS One*. **6**, e25482 (2011).
- 634 5. M. Zimmermann, M. Zimmermann-Kogadeeva, R. Wegmann, A. L. Goodman, Mapping human
635 microbiome drug metabolism by gut bacteria and their genes. *Nature*. **570**, 462–467 (2019).
- 636 6. C. Zhao, Y. Hu, H. Chen, B. Li, L. Cao, J. Xia, Y. Yin, An in vitro evaluation of the effects of
637 different statins on the structure and function of human gut bacterial community. *PLOS ONE*. **15**
638 (2020), p. e0230200.
- 639 7. B. W. Karlson, O. Wiklund, M. K. Palmer, S. J. Nicholls, P. Lundman, P. J. Barter, Variability of
640 low-density lipoprotein cholesterol response with different doses of atorvastatin, rosuvastatin,
641 and simvastatin: results from VOYAGER. *Eur Heart J Cardiovasc Pharmacother.* **2**, 212–217
642 (2016).
- 643 8. S. Tuteja, J. F. Ferguson, Gut Microbiome and Response to Cardiovascular Drugs. *Circulation:*
644 *Genomic and Precision Medicine*. **12** (2019), , doi:10.1161/circgen.119.002314.


6419. B. Tunland, *Human Microbiota in Health and Disease: From Pathogenesis to Therapy*
646 (Academic Press, 2018).
6420. H. Tilg, N. Zmora, T. E. Adolph, E. Elinav, The intestinal microbiota fuelling metabolic
648 inflammation. *Nat. Rev. Immunol.* **20**, 40–54 (2020).
6421. S. Vieira-Silva, G. Falony, E. Belda, T. Nielsen, J. Aron-Wisnewsky, R. Chakaroun, S. K.
650 Forslund, K. Assmann, M. Valles-Colomer, T. T. D. Nguyen, S. Proost, E. Prifti, V. Tremaroli, N.
651 Pons, E. Le Chatelier, F. Andreelli, J.-P. Bastard, L. P. Coelho, N. Galleron, T. H. Hansen, J.-S.
652 Hulot, C. Lewinter, H. K. Pedersen, B. Quinquis, C. Rouault, H. Roume, J.-E. Salem, N. B.
653 Søndertoft, S. Touch, MetaCardis Consortium, M.-E. Dumas, S. D. Ehrlich, P. Galan, J. P.
654 Gøtze, T. Hansen, J. J. Holst, L. Køber, I. Letunic, J. Nielsen, J.-M. Oppert, M. Stumvoll, H.
655 Vestergaard, J.-D. Zucker, P. Bork, O. Pedersen, F. Bäckhed, K. Clément, J. Raes, Statin
656 therapy is associated with lower prevalence of gut microbiota dysbiosis. *Nature.* **581**, 310–315
657 (2020).
6522. J. A. Caparrós-Martín, R. R. Lareu, J. P. Ramsay, J. Peplies, F. Jerry Reen, H. A. Headlam, N.
659 C. Ward, K. D. Croft, P. Newsholme, J. D. Hughes, F. O’Gara, Statin therapy causes gut
660 dysbiosis in mice through a PXR-dependent mechanism. *Microbiome.* **5** (2017), ,
661 doi:10.1186/s40168-017-0312-4.
6623. E. S. Istvan, J. Deisenhofer, Structural mechanism for statin inhibition of HMG-CoA reductase.
663 *Science.* **292**, 1160–1164 (2001).
6624. S. M. Grundy, N. J. Stone, A. L. Bailey, C. Beam, K. K. Birtcher, R. S. Blumenthal, L. T. Braun,
665 S. de Ferranti, J. Faiella-Tommasino, D. E. Forman, R. Goldberg, P. A. Heidenreich, M. A.
666 Hlatky, D. W. Jones, D. Lloyd-Jones, N. Lopez-Pajares, C. E. Ndumele, C. E. Orringer, C. A.
667 Peralta, J. J. Saseen, S. C. Smith, L. Sperling, S. S. Virani, J. Yeboah, 2018
668 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the
669 Management of Blood Cholesterol. *Journal of the American College of Cardiology.* **73** (2019),
670 pp. e285–e350.
6725. M. Arumugam, J. Raes, E. Pelletier, D. Le Paslier, T. Yamada, D. R. Mende, G. R. Fernandes,
672 J. Tap, T. Bruls, J.-M. Batto, M. Bertalan, N. Borruel, F. Casellas, L. Fernandez, L. Gautier, T.
673 Hansen, M. Hattori, T. Hayashi, M. Kleerebezem, K. Kurokawa, M. Leclerc, F. Levenez, C.
674 Manichanh, H. B. Nielsen, T. Nielsen, N. Pons, J. Poulain, J. Qin, T. Sicheritz-Ponten, S. Tims,
675 D. Torrents, E. Ugarte, E. G. Zoetendal, J. Wang, F. Guarner, O. Pedersen, W. M. de Vos, S.
676 Brunak, J. Doré, MetaHIT Consortium, M. Antolín, F. Artiguenave, H. M. Blottiere, M. Almeida,
677 C. Brechot, C. Cara, C. Chervaux, A. Cultrone, C. Delorme, G. Denariáz, R. Dervyn, K. U.
678 Foerstner, C. Friss, M. van de Guchte, E. Guedon, F. Haimet, W. Huber, J. van Hylckama-Vlieg,
679 A. Jamet, C. Juste, G. Kaci, J. Knol, O. Lakhdari, S. Layec, K. Le Roux, E. Maguin, A. Mérieux,
680 R. Melo Minardi, C. M’rini, J. Muller, R. Oozeer, J. Parkhill, P. Renault, M. Rescigno, N.
681 Sanchez, S. Sunagawa, A. Torrejon, K. Turner, G. Vandemeulebrouck, E. Varela, Y.
682 Winogradsky, G. Zeller, J. Weissenbach, S. D. Ehrlich, P. Bork, Enterotypes of the human gut
683 microbiome. *Nature.* **473**, 174–180 (2011).
6826. P. I. Costea, F. Hildebrand, M. Arumugam, F. Bäckhed, M. J. Blaser, F. D. Bushman, W. M. de
685 Vos, S. D. Ehrlich, C. M. Fraser, M. Hattori, C. Huttenhower, I. B. Jeffery, D. Knights, J. D.
686 Lewis, R. E. Ley, H. Ochman, P. W. O’Toole, C. Quince, D. A. Relman, F. Shanahan, S.
687 Sunagawa, J. Wang, G. M. Weinstock, G. D. Wu, G. Zeller, L. Zhao, J. Raes, R. Knight, P.
688 Bork, Enterotypes in the landscape of gut microbial community composition. *Nat Microbiol.* **3**, 8–
689 16 (2018).

69027. I. Holmes, K. Harris, C. Quince, Dirichlet multinomial mixtures: generative models for microbial
691 metagenomics. *PLoS One*. **7**, e30126 (2012).
69228. D. Vandeputte, G. Kathagen, K. D'hoë, S. Vieira-Silva, M. Valles-Colomer, J. Sabino, J. Wang,
693 R. Y. Tito, L. De Commer, Y. Darzi, S. Vermeire, G. Falony, J. Raes, Quantitative microbiome
694 profiling links gut community variation to microbial load. *Nature*. **551**, 507–511 (2017).
6929. S. M. Boekholdt, G. K. Hovingh, S. Mora, B. J. Arsenault, P. Amarenco, T. R. Pedersen, J. C.
696 LaRosa, D. D. Waters, D. A. DeMicco, R. J. Simes, A. C. Keech, D. Colquhoun, G. A. Hitman,
697 D. J. Betteridge, M. B. Clearfield, J. R. Downs, H. M. Colhoun, A. M. Gotto Jr, P. M. Ridker, S.
698 M. Grundy, J. J. P. Kastelein, Very low levels of atherogenic lipoproteins and the risk for
699 cardiovascular events: a meta-analysis of statin trials. *J. Am. Coll. Cardiol.* **64**, 485–494 (2014).
7000. A. Molinaro, The MetaCardis Consortium, P. B. Lassen, M. Henricsson, H. Wu, S. Adriouch, E.
701 Belda, R. Chakaroun, T. Nielsen, P.-O. Bergh, C. Rouault, S. André, F. Marquet, F. Andreelli,
702 J.-E. Salem, K. Assmann, J.-P. Bastard, S. Forslund, E. Le Chatelier, G. Falony, N. Pons, E.
703 Prifti, B. Quinquis, H. Roume, S. Vieira-Silva, T. H. Hansen, H. K. Pedersen, C. Lewinter, N. B.
704 Sønderskov, L. Køber, H. Vestergaard, T. Hansen, J.-D. Zucker, P. Galan, M.-E. Dumas, J.
705 Raes, J.-M. Oppert, I. Letunic, J. Nielsen, P. Bork, S. Dusko Ehrlich, M. Stumvoll, O. Pedersen,
706 J. Aron-Wisnewsky, K. Clément, F. Bäckhed, Imidazole propionate is increased in diabetes and
707 associated with dietary patterns and altered microbial ecology. *Nature Communications*. **11**
708 (2020), , doi:10.1038/s41467-020-19589-w.
7091. A. Katsuki, Y. Sumida, E. C. Gabazza, S. Murashima, M. Furuta, R. Araki-Sasaki, Y. Hori, Y.
710 Yano, Y. Adachi, Homeostasis model assessment is a reliable indicator of insulin resistance
711 during follow-up of patients with type 2 diabetes. *Diabetes Care*. **24**, 362–365 (2001).
7122. T. M. Wallace, J. C. Levy, D. R. Matthews, Use and abuse of HOMA modeling. *Diabetes Care*.
713 **27**, 1487–1495 (2004).
7133. M. C. Hunt, K. Solaas, B. F. Kase, S. E. H. Alexson, Characterization of an acyl-coA
715 thioesterase that functions as a major regulator of peroxisomal lipid metabolism. *J. Biol. Chem.*
716 **277**, 1128–1138 (2002).
7134. C. Depommier, A. Everard, C. Druart, H. Plovier, M. Van Hul, S. Vieira-Silva, G. Falony, J.
718 Raes, D. Maiter, N. M. Delzenne, M. de Barse, A. Loumaye, M. P. Hermans, J.-P. Thissen, W.
719 M. de Vos, P. D. Cani, Supplementation with *Akkermansia muciniphila* in overweight and obese
720 human volunteers: a proof-of-concept exploratory study. *Nat. Med.* **25**, 1096–1103 (2019).
7225. R. Cai, Y. Yuan, Y. Zhou, W. Xia, P. Wang, H. Sun, Y. Yang, R. Huang, S. Wang, Lower
722 Intensified Target LDL-c Level of Statin Therapy Results in a Higher Risk of Incident Diabetes: A
723 Meta-Analysis. *PLoS ONE*. **9** (2014), p. e104922.
7236. T. Wilmanski, N. Rappaport, J. C. Earls, A. T. Magis, O. Manor, J. Lovejoy, G. S. Omenn, L.
725 Hood, S. M. Gibbons, N. D. Price, Blood metabolome predicts gut microbiome α -diversity in
726 humans. *Nat. Biotechnol.* **37**, 1217–1228 (2019).
7237. T. Wilmanski, C. Diener, N. Rappaport, S. Patwardhan, J. Wiedrick, J. Lapidus, J. C. Earls, A.
728 Zimmer, G. Glusman, M. Robinson, J. T. Yurkovich, D. M. Kado, J. A. Cauley, J. Zmuda, N. E.
729 Lane, A. T. Magis, J. C. Lovejoy, L. Hood, S. M. Gibbons, E. S. Orwoll, N. D. Price, Gut
730 microbiome pattern reflects healthy ageing and predicts survival in humans. *Nat Metab.* **3**, 274–
731 286 (2021).

7328. J. C. Earls, N. Rappaport, L. Heath, T. Wilmanski, A. T. Magis, N. J. Schork, G. S. Omenn, J.
733 Lovejoy, L. Hood, N. D. Price, Multi-Omic Biological Age Estimation and Its Correlation With
734 Wellness and Disease Phenotypes: A Longitudinal Study of 3,558 Individuals. *J. Gerontol. A*
735 *Biol. Sci. Med. Sci.* **74**, S52–S60 (2019).
7369. O. Manor, C. L. Dai, S. A. Kornilov, B. Smith, N. D. Price, J. C. Lovejoy, S. M. Gibbons, A. T.
737 Magis, Health and disease markers correlate with gut microbiome composition across
738 thousands of people. *Nat. Commun.* **11**, 5206 (2020).
7390. C. M. Hales, *Prevalence of Obesity and Severe Obesity Among Adults: United States, 2017-*
740 *2018* (2020).
7441. C. Diener, S. Qin, Y. Zhou, S. Patwardhan, L. Tang, J. C. Lovejoy, A. T. Magis, N. D. Price, L.
742 Hood, S. M. Gibbons, Baseline Gut Metagenomic Functional Gene Signature Associated with
743 Variable Weight Loss Responses following a Healthy Lifestyle Intervention in Humans.
744 *mSystems*, e0096421 (2021).
7442. B. J. Callahan, P. J. McMurdie, M. J. Rosen, A. W. Han, A. J. A. Johnson, S. P. Holmes,
746 DADA2: High-resolution sample inference from Illumina amplicon data. *Nat. Methods.* **13**, 581–
747 583 (2016).
7483. E. S. Wright, DECIPHER: harnessing local sequence context to improve protein multiple
749 sequence alignment. *BMC Bioinformatics.* **16**, 322 (2015).
7504. M. N. Price, P. S. Dehal, A. P. Arkin, FastTree 2 – Approximately Maximum-Likelihood Trees for
751 Large Alignments. *PLoS ONE.* **5** (2010), p. e9490.
7525. P. J. McMurdie, S. Holmes, phyloseq: An R Package for Reproducible Interactive Analysis and
753 Graphics of Microbiome Census Data. *PLoS ONE.* **8** (2013), p. e61217.
7546. J. R. Bray, J. Roger Bray, J. T. Curtis, An Ordination of the Upland Forest Communities of
755 Southern Wisconsin. *Ecological Monographs.* **27** (1957), pp. 325–349.
7567. C. A. Lozupone, M. Hamady, S. T. Kelley, R. Knight, Quantitative and qualitative beta diversity
757 measures lead to different insights into factors that structure microbial communities. *Appl.*
758 *Environ. Microbiol.* **73**, 1576–1585 (2007).
7598. N. Zubair, M. P. Conomos, L. Hood, G. S. Omenn, N. D. Price, B. J. Spring, A. T. Magis, J. C.
760 Lovejoy, Genetic Predisposition Impacts Clinical Changes in a Lifestyle Coaching Program.
761 *Scientific Reports.* **9** (2019), , doi:10.1038/s41598-019-43058-0.
7629. M. P. Conomos, C. A. Laurie, A. M. Stilp, S. M. Gogarten, C. P. McHugh, S. C. Nelson, T. Sofer,
763 L. Fernández-Rhodes, A. E. Justice, M. Graff, K. L. Young, A. A. Seyerle, C. L. Avery, K. D.
764 Taylor, J. I. Rotter, G. A. Talavera, M. L. Daviglius, S. Wassertheil-Smoller, N. Schneiderman, G.
765 Heiss, R. C. Kaplan, N. Franceschini, A. P. Reiner, J. R. Shaffer, R. G. Barr, K. F. Kerr, S. R.
766 Browning, B. L. Browning, B. S. Weir, M. L. Avilés-Santa, G. J. Papanicolaou, T. Lumley, A. A.
767 Szpiro, K. E. North, K. Rice, T. A. Thornton, C. C. Laurie, Genetic Diversity and Association
768 Studies in US Hispanic/Latino Populations: Applications in the Hispanic Community Health
769 Study/Study of Latinos. *Am. J. Hum. Genet.* **98**, 165–184 (2016).

770


It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).



771

772 **Fig. 1 Plasma HMG correlates with statin use and statin LDL-response.** **A)** Frequency of statin use,
 773 type of statin taken, and number of participants with available data for each 'omics for each participant
 774 included in the present analysis. **B)** Diagram of *de novo* cholesterol synthesis pathway, with HMG and the
 775 rate-limiting enzyme inhibited by statins highlighted. **C)** Scatterplots of LDL-cholesterol and plasma HMG
 776 in statin non-users (blue) and users (red) separately, across two different clinical laboratory test vendors
 777 used in the cohort. The lines shown are the *y*-*x* regression lines, and the shaded regions are 95%
 778 confidence intervals for the slope of each line. Below each scatter plot is the Spearman correlation
 779 coefficient and corresponding *p*-value. *Adj. β*(95%CI) corresponds to the *β*-coefficient for LDL cholesterol
 780 from GLMs predicting plasma HMG, adjusted for sex, age, and BMI. Also shown to the right of each
 781 scatter plot are kernel density plots for plasma HMG in statin users and non-users. The black lines
 782 indicate the mean of each group, and the *p*-value corresponds to the effect size of the difference between
 783 statin users and non-users from GLMs adjusted for the same covariates as above. **D)** Relationship
 784 between statin intensity therapy and plasma HMG as well LDL cholesterol levels for the subset of
 785 participants in the cohort who had available dosage intensity data (*n*=97). The lines shown are the *y*-*x*
 786 regression lines, and the shaded regions are 95% confidence intervals for the slope of each line. *P*-value
 787 corresponds to the dose-response relationship between therapy intensity and either plasma HMG (top
 788 box plot) or LDL cholesterol (bottom box plot). Values on the *y*-axis are analyte levels adjusted for
 789 covariates (residuals). Box plots represent the interquartile range (25th to 75th percentile, IQR), with the
 790 middle line denoting the median; whiskers span 1.5 × IQR, points beyond this range are shown
 791 individually.

792



793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815

Fig.2 Gut microbiome composition is associated with markers of statin efficacy. A) Proportion of variance explained by statin use, plasma HMG levels, and a statin-by-HMG interaction term from unadjusted PERMANOVA models or models adjusted for sex, age, BMI, and microbiome vendor using the Weighted UniFrac genus-level dissimilarity matrix. Grey area corresponds to the cumulative R-squared of variables added to the model prior to the variable indicated on the x-axis, while the colored areas of the bars represent the additional variance explained by that variable. **B)** Measures of gut α -diversity in statin users compared to non-users. The β -coefficient, 95%CI and p-value shown is derived from OLS models predicting each of the α -diversity measures adjusted for microbiome vendor, sex, age, and BMI. Values on the y-axis are diversity measures adjusted for these covariates (residuals). **C)** Measures of Observed ASVs in statin users and non-users with known therapy intensity (low, moderate, high). P-values shown correspond to β -coefficients from OLS models predicting Observed ASVs comparing each intensity group to the no statin control group, adjusted for the same covariates as in B). **D)** Plasma HMG levels among statin users and non-users across tertiles of gut α -diversity. Interaction P corresponds to the statin-by- α -diversity interaction term p-value from GLM predicting plasma HMG adjusted for the same covariates as in B) and C). Values on the y-axis are diversity measures adjusted for these covariates (residuals). Box plots represent the interquartile range (25th to 75th percentile, IQR), with the middle line denoting the median; whiskers span $1.5 \times$ IQR, points beyond this range are shown individually. **E)** Scatter plots of Observed ASVs (x-axis) and covariate adjusted plasma HMG levels (residuals) (y-axis) in statin users with known dosage therapy intensity as well as statin non-users. Levels were adjusted for the same covariates as in B), as well as dosage intensity.

816
817
818
819




Fig. 3: Statin associations with markers of efficacy and metabolic side effects are microbiome enterotype dependent. **A)** Principal Coordinate Analysis (PCoA) plot of the genus-level Bray-Curtis Dissimilarity matrix color-coded by enterotypes. **B-D)** Relative abundance of *Bacteroides* (B), *Prevotella* (C), and *Faecalibacterium* (D) genera across the four enterotypes identified in the cohort. **E)** Proportion of each enterotype in statin users and non-users across the whole cohort (left) and stratified by obesity status (right). **F)** Plasma HMG levels among statin users and non-users stratified by enterotype. Interaction P corresponds to the statin-by-enterotype interaction term p-value from unadjusted ANOVA models, while the cov. Adj. interaction P corresponds to the statin-by-enterotype interaction term p-value from covariate adjusted ANCOVA models. Plasma HMG levels shown on the y-axis are values adjusted for the same covariates (residuals). **G)** HOMA-IR measures among statin users and non-users stratified by enterotype. Interaction P corresponds to the statin-by-enterotype interaction term p-value from unadjusted ANOVA models, while the cov. Adj. interaction P corresponds to the statin-by-enterotype interaction term p-value from ANCOVA models adjusted for covariates. P-values above the box plots in F) and G) correspond to tests of significance between statin non-users and statin users within each enterotype using two-samples t-test. Differences with Bonferroni corrected $P < 0.05$ were considered statistically significant and are highlighted in red. Box plots represent the interquartile range (25th to 75th percentile, IQR), with the middle line denoting the median; whiskers span $1.5 \times$ IQR, points beyond this range are shown individually.

820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842

843

844

845

	<100 mg/dL (n cases=132, N total=197)		<70 mg/dL (n cases=44, N total=197)	
	Cov. adj. OR(95%CI)	Cov. & T2D adj. OR(95%CI)	Cov. adj. OR(95%CI)	Cov. & T2D adj. OR(95%CI)
Shannon diversity	0.69 (0.49-0.97)	0.72 (0.50-1.03)	0.67 (0.48-0.95)	0.60 (0.41-0.87)
Observed ASVs	0.67 (0.47-0.95)	0.67 (0.45-0.98)	0.66 (0.45-0.95)	0.62 (0.40-0.96)
Bac.2 enterotype	2.19 (1.04-4.60)	2.11 (0.95-4.66)	3.61 (1.68-7.77)	4.33 (1.83-10.25)

846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874

875

876

877


878
879
880

Table 1. Gut microbiome measures correlate with having reached LDL-cholesterol target levels among statin users. Odds Ratios (OR) for each gut microbiome measure from logistic regression models predicting having achieved either <100 mg/dL or <70 mg/dL target LDL-cholesterol level among statin users. The *Bac.2* enterotype was compared against all other enterotypes. Measures of α -diversity were scaled and centered prior to analysis for easier comparison of effect sizes. Models were adjusted for clinical laboratory and microbiome vendors, age, sex, and BMI. Further adjustment for T2D status was done in participants where this information was available (n=174). Significant OR (P<0.05) are highlighted in red.

Measure	Percent median increase in each measure and P-value Between statin-users and non-users for each enterotype				F-value and corresponding P-value for statin*enterotype interaction term predicting each measure		
	<i>Bac.1</i>	<i>Rum.</i>	<i>Bac.2</i>	<i>Prev.</i>	Unadjusted model N=1848	Covariate adj. model N=1848	Covariate and diabetes adj. model N=1691
HOMA-IR	73%, <i>P=7.2e-07</i>	21% P=0.27	99% <i>P=1.2e-04</i>	29% P=0.33	F=4.5, P=0.0037	F=2.6, P=0.0495	F=2.6, P=0.049
Insulin	63% <i>P=5.6e-06</i>	19% P=0.17	89% <i>P=9.1e-04</i>	22% P=0.25	F=3.0, P=0.032	F=1.4, P=0.23	F=1.5, P=0.22
Glucose	6.6% <i>P=9.7e-04</i>	4.5% P=0.51	9.3% <i>P=8.1e-04</i>	7.6% P=0.84	F=6.4, P=0.00025	F=4.4, P=0.0041	F=3.9, P=0.0092
HbA1c	5.6% <i>P=2.0e-03</i>	1.9% P=0.16	7.3% <i>P=1.2e-04</i>	1.8% P=0.57	F=8.1, P=2.3E-05	F=6.3, P=0.00030	F=3.4, P=0.017

881
882 **Table 2. Gut microbiome enterotypes modify the association between statin use and markers of**
883 **glucose homeostasis.** Percent median increase in the first four columns corresponds to the percent
884 difference in each marker between statin users and non-users within each enterotype. P-values in these
885 columns correspond to t-tests comparing covariate adjusted values between statin users and non-users.
886 Values shown are raw p-values, and those that remained significant after correcting for type-1-error
887 (Bonferroni $P < 0.05$) are highlighted in red. The last three columns in the table show the F- and p-values
888 for the statin-by-enterotype interaction term from ANOVA (unadjusted) and ANCOVA (covariate adjusted)
889 models predicting each of the specified markers of glucose homeostasis. Covariate adjusted models were
890 adjusted for microbiome vendor, clinical lab vendor, sex, age, BMI, LDL cholesterol and plasma HMG.
891 Last column corresponds to models adjusted for the same covariates as well as T2D status (yes/no,
892 N=1691, T2D n=64). P-values < 0.05 are colored in red. Abbreviations: HOMA-IR: Homeostatic Model
893 Assessment for Insulin Resistance; HbA1c: Glycated Hemoglobin A1c.
894
895
896
897
898
899
900
901
902
903
904
905


It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).



906
907
908


909 **Fig. S1. Gut alpha-diversity is anti-correlated with markers of statin on-target effects. A)**
910 LDL-cholesterol and plasma HMG measures in individuals stratified by statin use and genotype.
911 Provided is the P-value for the statin-by-SNP interaction term from GLM (HMG) or OLS (LDL)
912 models adjusted for sex, age, BMI and the first 7 ancestry principle components. **B)** Proportion
913 of variance explained by statin use, plasma HMG levels, and a statin-by-HMG interaction term
914 from unadjusted PERMANOVA models (statin use + HMG + statin use-by-HMG) or models
915 adjusted for sex, age, BMI, and microbiome vendor using the Bray-Curtis genus-level
916 dissimilarity matrix. Grey area corresponds to the cumulative R-squared of variables added to
917 the model prior to the variable indicated on the x-axis, while the colored areas of the bars
918 represent the additional variance explained by that variable. **C)** Measures of Observed ASVs in
919 non-users and across statin users with known therapy intensity (low, moderate, high). **D-E)**
920 Scatter plots of Shannon diversity (x-axis) and covariate adjusted plasma HMG levels (y-axis) in
921 statin users with known dosage therapy intensity (D) and statin non-users (E). HMG values
922 have been adjusted for the same covariates as in B), as well as statin intensity. Also provided
923 are the spearman correlation coefficients and their corresponding P-value, as well as adjusted
924 β -coefficients from GLM predicting HMG levels adjusted for the same covariates as in C) as well
925 as dosage intensity. **F-G)** Scatter plots of Shannon diversity (x-axis) and covariate adjusted
926 LDL-cholesterol levels (y-axis) in all statin users (F) and statin users with known therapy
927 intensity (G), where LDL values were further adjusted for therapy intensity. **F)** Scatter plot of
928 Shannon diversity (x-axis) and covariate adjusted LDL-cholesterol (y-axis) in statin non-users
929 adjusted for the same covariates as in F).

930
931
932
933
934



935
936 **Fig. S2. Enterotypes differ in their relative abundance of SCFA-producing taxa. A)**
937 Measure of model fit using the Bayesian information criterion (BIC) (top) across an increasing
938 number of Dirichlet components as well as Laplace approximation (bottom) in the Arivale cohort.
939 Specifying 4 components resulted in best model performance using BIC and is highlighted by
940 the dotted red line. **B)** Gut alpha-diversity measures using Observed ASVs across the four
941 enterotypes. **C-D)** Relative abundance of the genus *Akkermansia* (C) and *Subdoligranulum* (D)
942 across the four enterotypes identified in the Arivale cohort. P-value from a non-parametric
943 Kruskal-Wallis test comparing differences across all four enterotypes is provided in the top right
944 corner. **D)** HOMA-IR levels across statin non-users and statin users with known therapy
945 intensity. To the right are the β -coefficients, 95% confidence intervals, and P-values from OLS
946 regression models predicting log(HOMA-IR) adjusted for clinical lab vendor, microbiome vendor,
947 sex, age, BMI, and LDL cholesterol. HOMA-IR values on the y-axis have been adjusted for the
948 same covariates. Box plots represent the interquartile range (25th to 75th percentile, IQR), with
949 the middle line denoting the median; whiskers span $1.5 \times$ IQR, points beyond this range are
950 shown individually.

951
952
953
954
955
956
957



958
 959 **Fig. S3: Microbiome enterotypes modify markers of statin on and off-target effects. A)**
 960 Blood LDL-cholesterol levels among statin users and non-users stratified by enterotype.
 961 Interaction P corresponds to the statin-by-enterotype interaction term P-value from unadjusted
 962 ANOVA models, while the cov. Adj. interaction P corresponds to the statin-by-enterotype
 963 interaction term P-value from ANCOVA models adjusted for clinical lab vendor, microbiome
 964 vendor, sex, age, BMI and LDL cholesterol. Values shown on the y-axis are values adjusted for
 965 the same covariates (residuals). **B)** HbA1c measures among statin users and non-users
 966 stratified by enterotype. Interaction P corresponds to an unadjusted interaction term P-value as
 967 in A), while the cov. Adj. interaction P corresponds to the statin-by-enterotype interaction term
 968 P-value from ANCOVA models adjusted for clinical lab vendor, microbiome vendor, sex, age,
 969 BMI, HMG and LDL cholesterol. Values shown on the y-axis are values adjusted for the same
 970 covariates (residuals). P-values above the box plots across A)-B) correspond to tests of
 971 significance between statin non-users and statin users within each enterotype using two-
 972 samples t-test on covariate adjusted values (residuals). Differences with Bonferroni corrected
 973 $P < 0.05$ were considered statistically significant and are highlighted in red. Box plots represent
 974 the interquartile range (25th to 75th percentile, IQR), with the middle line denoting the median;
 975 whiskers span $1.5 \times$ IQR, points beyond this range are shown individually.

976

	No. of missing values	Non-users (n=1604)	Statin users (n=244)	Whole cohort (n=1848)	P-Value	Statistical Test
Mean Age (s.d.)	0	47.3 (10.9)	59.1 (10.1)	48.8 (11.5)	<0.001	Two Sample T-test
Mean BMI (s.d.)	0	27.8 (6.5)	30.1 (6.2)	28.1 (6.5)	<0.001	Two Sample T-test
Mean LDL (mg/dL) (s.d.)	0	115.9 (32.8)	95.0 (28.8)	113.2 (33.1)	<0.001	Two Sample T-test
Median HOMA-IR (index) [IQR]	0	1.8 [1.3,2.8]	3.1 [2.0,5.1]	1.9 [1.3,3.1]	<0.001	Kruskal-Wallis
Mean Glucose (mg/dL) (s.d.)	0	92.9 (16.5)	106.7 (35.9)	94.7 (20.7)	<0.001	Two Sample T-test
Diabetes (n)(%)	157	26 (1.8)	40 (18.7)	66 (3.9)	<0.001	Chi-squared
Sex (n) (% Female)	0	1046 (65.2)	119 (48.8)	1165 (63.0)	<0.001	Chi-squared
Clinical lab vendor (n) (% Quest)	0	463 (28.9)	90 (36.9)	553 (29.9)	0.013	Chi-squared
Microbiome vendor (n) (% DNAGenotek)	110	689 (45.8)	112 (48.1)	801 (46.1)	0.56	Chi-squared
Race (% white)	72	1227 (80.1)	207 (84.8)	1434 (80.7)	0.097	Chi-squared

977 **Table S1. Arivale participant demographics stratified by statin use.** No. of missing values
 978 corresponds to the total number of missing values across the cohort due to either participants
 979 not providing that information (diabetes status, race) or not having that omics data available
 980 (microbiome). 'P-Value' corresponds to statistical analysis testing the difference between statin
 981 users and non-users, with the type of statistical test used shown in the last column.
 982 Abbreviations: BMI: body mass index; LDL: low-density lipoprotein cholesterol; HOMA-IR:
 983 Homeostatic Model Assessment for Insulin Resistance; IQR: interquartile range.

984
 985
 986
 987
 988
 989
 990
 991
 992
 993

SNP rsid	At least one copy of the minor allele (proportion)	HMG (N=1734)				LDL-Cholesterol (N=1734)			
		Adj. β -coeff	s.e.	P-value	Corr. P-value	Adj. β -coeff	s.e.	P-value	Corr. P-value
rs10455872	0.11	-0.0207	0.0338	0.5402	0.6690	-4.5819	3.5322	0.1947	0.4333
rs2199936	0.23	-0.0157	0.0245	0.5211	0.6690	-0.2432	2.5747	0.9247	0.9966
rs2900478	0.29	-0.0110	0.0237	0.6427	0.6690	1.0850	2.4733	0.6609	0.9966
rs4420638	0.30	-0.0178	0.0228	0.4350	0.6690	-3.4403	2.3689	0.1466	0.4333
rs445925	0.18	0.0907	0.0324	0.0052	0.0207	-0.0143	3.3645	0.9966	0.9966
rs7412	0.12	0.1513	0.0453	0.0009	0.0068	0.7567	4.6668	0.8712	0.9966
rs646776	0.37	0.0096	0.0224	0.6690	0.6690	4.1731	2.3359	0.0742	0.4333
rs8014194	0.46	0.0347	0.0215	0.1068	0.2849	2.7833	2.2520	0.2166	0.4333

994
995
996
997
998
999
1000
1001
1002
1003

Table S2. Correspondence of HMG with SNPs previously associated with statin response. β -coefficients, standard error (s.e.) and the corresponding p-value for the SNP-by-statin interaction term predicting either HMG (GLM) or LDL-cholesterol levels (OLS regression) across the Arivale cohort with available genetics data. Models were adjusted for sex, age, BMI and the first 7 ancestry PCs. “Corr. P-value” corresponds to the P-value for each β -coefficient after correcting for multiple hypothesis testing (FDR<0.05). Significant P-values are highlighted in red.

1004
1005
1006
1007
1008

Data S1. Significant genus differences across enterotypes. List of 85 genera significantly differing across enterotypes tested using a Kruskal-Wallis test (Bonferroni $P<0.05$). Each enterotype column corresponds to the median relative abundance of a particular genus for that enterotype.

1009
1010
1011
1012